TOP216

Background Previously reported results from JALSG CML212 (UMIN000007909), a multicenter open-labeled prospective randomized controlled phase 3 study on de novo chronic myeloid leukemia in chronic phase (CML-CP), showed that cumulative achievement rates of MR4.5 (BCR-ABL1 ≤0.0032% on the International Scale [BCR-ABL1IS]) by 18 months were 33.0% (75/227) (95% CI:27.0–39.6%) in the nilotinib arm and 30.8% (70/227) (95% CI: 24.9–37.3%) in the dasatinib (DAS) arm, with no significant difference...After stopping DAS, 59.2% of patients remained in TFR 12 months later. The results suggest that a higher proportion of patients with CML-CP who achieved sustained MR4.5 on frontline DAS will remain progression free without treatment compared with that in previous TFR trials.

Background Previously reported results from JALSG CML212 (UMIN000007909), a multicentrer open-labeled prospective randomized controlled phase 3 study on de novo chronic myeloid leukemia in chronic phase (CML-CP), showed that cumulative achievement rates of MR4.5 (BCR-ABL1 ≤0.0032% on the International Scale [BCR-ABL1IS]) by 18 months were 33.0% (75/227) (95% CI:27.0–39.6%) in the nilotinib (NIL) arm and 30.8% (70/227) (95% CI: 24.9–37.3%) in the dasatinib arm, with no significant difference...After stopping NIL, 76.5% of patients remained in TFR at 12 months later. The results suggest that a higher proportion of patients with CML-CP who achieved sustained MR4.5 on frontline NIL will remain progression free without treatment compared with that in previous TFR trials.